(1347133) New Immune Targets in Sepsis

For the past 50 years, sepsis has been defined as a microbial infection that produces fever or hypothermia, tachycardia, tachypnea, and blood leukocyte changes. Sepsis is now increasingly being considered a dysregulated systemic inflammatory and immune response to microbial invasion that produces organ injury. Mortality rates are declining to 15% to 25%, an improvement from 30% to 50% that has resulted from aggressive early diagnosis and early antibiotics. Still, one in three patients admitted to the hospital with sepsis will die. Sepsis manifests as prolonged inflammation, immune suppression, and organ injury. Survivors have a continued risk of mortality after discharge, as well as long-term cognitive and functional deficits. How can we functionally understand a patient's immune state, deploy effectively therapies, and modulate our understanding of future theranostics? This session will focus on novel and targeted therapies in sepsis management and current evidence to improve understanding of current research that may directly impact patients with sepsis in the future. Speakers will present four separate and unique approaches to patients with hyperinflammation and/or immunoparalysis. Use of pathogen-specific, neutrophil-targeted therapies, host immune responses to hemolysis, and restoration of adaptive immune function are becoming promising therapies in sepsis and will be discussed, along with unique ways to immune-phenotype patients.